RS-2025-02213314

Phase 1 IND Approval for Next-Generation Functionally Enhanced Tumor Infiltrating Lymphocyte (TIL) Cell Therapy for Recurrent Ovarian Cancer

CHA Biotech Co., Ltd

CHA Biotech
㈜차바이오텍

ONCOLOGY | **Preclinical**

Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Recurrent Ovarian Cancer (platinum-resistant and platinum-sensitive)
Target	T cell
MoA(Mechanism of Action)	• The pre-treatment of IL-7 or/and PD-(L)1 blockade prior to tumor resection might drive a prolonged anti-tumor response via increased population of stem-like CD8+ T cells. • CHATIL-102-OC selectively expands MUC-1-reactive T cells using proprietary cytokine cocktail and co-stimulation to reinforce the cytotoxic function and memory formation. • Both chemotherapy-based preconditioning to restrain immunosuppressive cells and multiple doses of functionally enhanced TILs enable the durable anti-tumor immunity.
Competitiveness	• Naturally derived autologous T cells without gene modification • Recognition of multiple tumor-associated antigens • Minimal off-tumor toxicity • Superior safety profile • Efficacy against solid tumors
Development Stage	Preclinical
Route of Administration	Intravenous, 3 doses every 3 weeks